Antagonists of IL-6 to prevent or treat thrombosis
AssigneeAlderbio Holdings LLC
InventorJeffrey T. L. Smith
Life of this patent
Estimating the term…
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
Claims46
A method of reducing the risk of hypercoagulation or thrombosis in a subject having an elevated IL-6 level and an elevated D-dimer level by reducing the level of serum D-dimer in said subject, comprising administering to the subject an amount of an IL-6 antagonist, wherein said IL-6 antagonist is an antibody or antibody fragment that specifically binds human IL-6, wherein said antibody or antibody fragment comprises a variable light (VL) region containing the VL complementarity regions, CDR1, CDR2 and CDR3, respectively in SEQ ID NO:4, 5 and 6, and comprises a variable heavy (VH) region containing the VH complementarity regions, CDR1, CDR2 and CDR3, respectively in SEQ ID NO:7, 8 or 120 and 9, and which antibody or fragment is administered in an amount effective to reduce the level amount of serum D-dimer thereby reducing the risk of hypercoagulation or thrombosis in said subject.
Dependencies are inferred from the claim text.